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Abstract: Ticagrelor is a novel P2Y12 receptor antagonist which, like clopidogrel and prasugrel, 
functions by blocking adenosine diphosphate-mediated platelet aggregation. However, unlike 
the aforementioned agents, the binding of ticagrelor to this receptor is reversible. Ticagrelor is 
also believed to mediate some of its beneficial effects by augmenting the effects of adenosine, 
which is another unique pharmacologic property of this drug. In terms of antiplatelet effect, 
ticagrelor is more potent than clopidogrel and produces a faster and stronger inhibition of 
platelet aggregation. This may also be an advantage of ticagrelor over prasugrel, but this has not 
been adequately studied. Due to the reversible nature of the binding of ticagrelor to the platelet 
receptor, ticagrelor has a relatively fast offset of effect, with platelet aggregation approaching 
pretreatment levels about 3 days after discontinuation of therapy. This has advantages in patients 
requiring invasive procedures, but also makes medication adherence very important in order to 
be able to maintain an effective antiplatelet effect. Ticagrelor has been shown to be clinically 
superior to clopidogrel when given to patients with an acute coronary syndrome, resulting in 
significantly lower rates of myocardial infarction and vascular death. However, ticagrelor is 
indicated to be administered with aspirin, and the clinical benefits of ticagrelor may be less 
when daily dosages of aspirin exceed 100 mg. As expected, bleeding is the most common 
adverse effect with ticagrelor, although it occurs at rates comparable with those seen for clopi-
dogrel with the exception of noncoronary artery bypass graft-related major bleeding and fatal 
intracranial bleeds, the latter of which occurs only rarely. Dyspnea is another common adverse 
effect with ticagrelor, although this is usually not severe and resolves with drug discontinua-
tion. Unlike clopidogrel, there are no known pharmacogenomic concerns with ticagrelor, and 
emerging data suggest ticagrelor to be effective in patients resistant to clopidogrel, although 
more study is needed on this topic. While preliminary data suggest ticagrelor to be cost effective 
when compared with generic clopidogrel, the acquisition cost of ticagrelor is not insignificant 
and this will likely be an issue for many health care organizations. Currently, ticagrelor is well 
positioned to assume an active role in the treatment of coronary artery disease due to an impres-
sive efficacy profile and reasonable safety. Its ultimate role in therapy will continue to evolve 
as studies on this drug continue eg, (Prevention of Cardiovascular Events in Patients with Prior 
Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin, PEGASUS)   
and more information hopefully becomes available on its use in clopidogrel nonresponders and 
relative safety and efficacy compared with prasugrel.
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Introduction
Patients with acute coronary syndromes (ACS) have high platelet activation which 
leads to thrombus formation and myocardial ischemia.1 Platelets have   numerous Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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ways of becoming activated, so there are numerous 
  targets for drugs which inhibit platelet function. Current 
antiplatelet agents available to clinicians for treating and 
preventing ACS include aspirin, glycoprotein IIb/IIIa 
receptor antagonists (tirofiban, abciximab, and eptifi-
batide), thienopyridines (clopidogrel and prasugrel), and 
ticagrelor. Aspirin inhibits cyclo-oxygenase-1 in platelets, 
which decreases thromboxane A2 concentrations. While 
aspirin reduces thrombotic events, stroke, and myocardial 
infarction by approximately 20%–25% through decreased 
platelet activation, this drug results in only partial inhibition 
of platelet aggregation (IPA).2,3 This has led to the use of 
other antiplatelet drugs with different mechanisms of action 
in addition to aspirin. Secondary prevention of recurrent 
thrombotic episodes sometimes requires the use of two 
antiplatelet agents with different mechanisms of action, ie, 
dual antiplatelet therapy. Dual antiplatelet therapy is now 
considered standard of care for patients with ACS with or 
without stenting.4,5
Thienopyridines (clopidogrel and prasugrel) work by 
covalently and irreversibly binding to the adenosine diphos-
phate (ADP) site on the P2Y12 receptor, thereby preventing 
ADP-mediated platelet aggregation for the life of the platelet 
(Figure 1). The most utilized drug in this class is clopidogrel 
which has been shown to be beneficial in patients with ACS 
regardless of whether or not percutaneous coronary interven-
tion is performed.6,7 Clopidogrel is a prodrug which needs to 
be converted to an active metabolite via hepatic activation 
mainly through cytochrome P450 (CYP) 2C19 and 3A4. This 
leads to delayed antiplatelet activity and potential interpatient 
variability because of genetic polymorphisms in CYP2C19, 
leading to increased or decreased activity of this enzyme. 
Prasugrel is also a prodrug which requires hepatic activation 
but, unlike clopidogrel, this drug is activated much faster 
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Figure 1 Adenosine diphosphate (ADP) binds to the P2Y12 receptor. This binding results in activation of the platelet which causes a conformational shape change, activation 
of the glycoprotein (GP) iib/iiia receptors, and platelet aggregation. Ticagrelor binds at a site on the P2Y12 receptor that is separate from the ADP binding site and produces 
a non-competitive inhibition, while the thienopyridines, clopidogrel and prasugrel, bind directly to the ADP binding site on the P2Y12 receptor permanently blocking this site.   
Antiplatelet agents that block the P2Y12 receptor have complementary effects with aspirin in terms of platelet inhibition because their mechanism of action is different than 
that of aspirin, which blocks cyclo-oxygenase-1 causing a decrease in thromboxane A2.
Abbreviations: 5HT, 5-hydroxytryptamine; α, alpha granules; δ, dense granules; ADP, adenosine diphosphate; ATP, adenosine triphosphate; COX-1, cyclo-oxygenase-1; 
GP, glycoprotein; TPα, thromboxane A2 receptor; TxA2, thromboxane A2.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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and has better IPA. Studies have shown greater efficacy as 
well as more bleeding risk with prasugrel compared with 
clopidogrel.8
Ticagrelor is chemically, pharmacologically, and phar-
macokinetically different to the thienopyridines (Figure 2). 
This article will review the current literature surrounding 
the pharmacology, pharmacokinetics, clinical outcomes, 
adverse events, and practical therapeutic considerations 
with ticagrelor.
A literature search was conducted as recently as 
  September 2011 using PubMed with the following 
search terms: “ticagrelor,” “Brilinta,” “PLATO trial,” 
“  pharmacokinetics,” “pharmacodynamics,” “platelet aggre-
gation,” “platelet activation”, and “antiplatelet drugs.” These 
terms were cross-referenced with each other. The literature 
search was only limited to articles published in English. 
There were no other limits so that a larger amount of stud-
ies could be collected and analyzed for utility. Additional 
articles were found by reviewing and cross-checking the 
references of relevant articles. Product package inserts and 
some other product-specific information were obtained from 
the manufacturers’ individual websites. The United States 
Food and Drug Administration website (fda.gov) was also 
reviewed for pertinent information.
Pharmacology
ADP is a potent chemical stimulator of platelet activation. 
ADP binds to and activates two different G-protein coupled 
receptors, P2Y1 and P2Y12. Activation of the P2Y1 receptor 
leads to reversible platelet aggregation and shape change, 
while activation of the P2Y12 receptor leads to a slower 
platelet aggregation that is more sustained and is not involved 
in any shape change. Both of these receptors need to be 
activated by ADP at the same time to elicit a typical platelet 
aggregation response.9 Of the two receptors, P2Y12 is more 
tissue-selective, which makes this receptor an ideal target 
for drug therapy.9
Both the thienopyridines and ticagrelor are P2Y12 recep-
tor antagonists. Ticagrelor is not a thienopyridine, but rather 
belongs to a new class of P2Y12 receptor inhibitors known as 
cyclopentyl-triazolo-pyrimides. This drug is a very selective 
antagonist for the P2Y12 receptor on platelets and, unlike the 
thienopyridines, binds reversibly to this receptor. Also, unlike 
clopidogrel or prasugrel, ticagrelor allows ADP to bind to 
the P2Y12 receptor because this drug binds on a site that is 
distant from the ADP site on the P2Y12 receptor (Figure 1). 
This noncompetitive inhibition blocks the conformational 
change of this receptor which is responsible for downstream 
activation of platelet aggregation.10 When ticagrelor leaves 
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the site on the P2Y12 receptor it does not alter the receptor 
which allows it to engage in conformational changes accord-
ing to the appropriate stimuli, such as ADP binding.
Ticagrelor has additional benefits beyond the inhibi-
tion of P2Y12 receptors on platelets. These P2Y12 receptors 
are also found in vascular smooth muscle which mediates 
  vasoconstriction. Ticagrelor has the ability to enter the smooth 
muscle of the vasculature and inhibit local P2Y12 receptors, 
thereby causing vasodilation. This ability to inhibit P2Y12 recep-
tors in the vascular smooth muscle is unique to   ticagrelor.10 
Another additional benefit of ticagrelor has to do with the 
ability of this drug to augment the effects of endogenous 
  adenosine. During ACS, adenosine is released, which serves 
several beneficial functions, one of which is to increase coro-
nary blood flow. There is typically an accumulation of adenos-
ine in response to tissue ischemia and injury which occurs 
during ACS. Adenosine also acts as an anti-inflammatory 
and cardioprotective agent by improving preconditioning and 
postconditioning and preventing sudden death.11 The chemi-
cal structure of ticagrelor is very similar to that of adenosine 
(Figure 2). It is theorized that ticagrelor loses two key struc-
tures after oral administration, ie, propyl sulfate and benzo-
difluoride, by either oxygenase and/or radical fragmentation 
pathways. In this sense, ticagrelor is effectively a precursor 
of adenosine because, after the loss of these structures, the 
resulting compound is essentially adenosine.11 Ticagrelor also 
inhibits uptake of adenosine by erythrocytes during ACS. The 
mechanism for this is thought to be inhibition of the sodium-
independent equilibrative nucleoside transporters subtype 1. 
This transporter regulates the influx and efflux of adenosine 
particularly in cardiac myocytes.12 This adenosine uptake 
inhibition appears to be dose-dependent and is 30–50-fold less 
potent compared with its ability to inhibit platelets.10,13 This 
results in augmentation of the coronary blood flow induced by 
adenosine by prolonging its half-life and increasing systemic 
exposure to this agent.10,13
Pharmacokinetics
Findings from pharmacokinetic studies in healthy volunteers 
and patients with atherosclerosis have provided most of the 
pharmacokinetic information available for ticagrelor.14–17 
Ticagrelor is only available by the oral route and, at doses 
ranging from 100 to 400 mg per day, has rapid absorption from 
the gastrointestinal tract with peak plasma concentrations 
being achieved in a median of 1.5 hours and 3 hours for the 
parent compound and active metabolite (AR-C124910XX), 
respectively.17 Inhibition of platelet aggregation of 80%–90% 
is seen within 2–4 hours after a single oral dose of ticagrelor 
of 180 mg.15 The IPA is dose-dependent; however there is 
very little increase in IPA with doses greater than 100 mg 
twice daily.16,17 The half-lives of the parent drug and active 
metabolite are 8 and 12 hours, respectively. This, along with 
the reversible effects of the drug on platelet aggregation, 
necessitates twice daily dosing for ticagrelor. At 24 hours 
after a single ticagrelor dose of 300 mg and 400 mg, the mean 
IPAs were 75% and 85%, respectively.16 The IPAs achieved 
by ticagrelor were higher than the IPA typically seen with 
clopidogrel, which is around 50%.18 Pharmacokinetic studies 
have shown that ticagrelor is mainly restricted to the plasma 
space, which is where it will interact with platelets and the 
smooth muscle of the vasculature.16 Ticagrelor is primarily 
metabolized hepatically by CYP3A4 and CYP3A5. Therefore, 
ticagrelor metabolism, blood levels, and ultimately pharmaco-
logic effects, may be affected by other medications (eg, keto-
conazole) or substances (eg, St John’s wort) that inhibit or 
induce CYP3A4 and/or 3A5 enzymes. While ticagrelor does 
not need to be bioactivated to inhibit platelet aggregation 
there is one active metabolite, ie, AR-C124910XX. The two 
enzymes most responsible for the production of this sole 
active metabolite are CYP3A4 and CYP3A5.19 This active 
metabolite has plasma concentrations that are approximately 
one third that of its parent compound and is considered to be 
equipotent in terms of antiplatelet effects. Ticagrelor appears 
to inhibit CYP2C9 moderately and induce CYP2B6 weakly.19 
Ticagrelor is mainly excreted in the feces with very little of 
the parent drug and active metabolite (,0.05%) excreted 
unchanged in the urine. Therefore, no dosage adjustment 
is needed in patients with kidney dysfunction.20   Ticagrelor 
has also been studied in volunteers with mild hepatic 
  impairment.21 The mean maximum concentration, area under 
the curve, and half-live of ticagrelor and its active metabolite 
were higher in volunteers with Child-Pugh class A compared 
with healthy volunteers but these differences are unlikely to 
be clinically significant and therefore no dosage adjustment 
is necessary in patients with mild liver dysfunction. There 
have been no studies looking at moderate (Child-Pugh B) or 
severe (Child-Pugh C) hepatic dysfunction. The prescribing 
information for ticagrelor does not provide specific dosing 
recommendations in patients with moderate hepatic impair-
ment and states that the drug is contraindicated in patients 
with severe hepatic impairment.20
Comparative antiplatelet effects  
of ticagrelor and clopidogrel
The Dose confIrmation Study assessing antiPlatelet Effects 
of AZD6140 versus clopidogRel in non-ST-segment Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
477
Ticagrelor in acute coronary syndrome
Elevation myocardial infarction (DISPERSE) evaluated the 
  pharmacodynamics, pharmacokinetics, safety, and tolerability 
of various dosages of ticagrelor (AZD6140) versus clopidogrel 
in patients receiving aspirin therapy.17 This was a randomized, 
double-blind, parallel-group study conducted in patients with 
known atherosclerotic disease. The dosages of ticagrelor were 
50 mg twice daily (n = 41), 100 mg twice daily (n = 39), 200 mg 
twice daily (n = 37), or 400 mg once daily (n = 46) and the dose 
of clopidogrel was 75 mg once daily (n = 37).   Treatments were 
given for 28 days and all patients received aspirin 75–100 mg 
once daily. Platelet aggregation was analyzed via optical 
aggregometry of platelet-rich plasma taken from blood sam-
ples of the patients at times 0 (  predose), 2, 4, 8, and 12 hours 
(post-dose) on days 1, 14, and 28 and post-dose at 24 hours 
on days 14 and 28. The IPA was measured using 20 µM ADP 
as the agonist. The safety of the trial medication was assessed 
by reports of adverse events, including bleeding. The results 
showed ticagrelor at dosages of 100 mg twice daily, 200 mg 
twice daily, and 400 mg once daily inhibited ADP-induced 
platelet aggregation to a greater extent compared with either 
clopidogrel or ticagrelor 50 mg twice daily. The three higher 
dosages of ticagrelor did not differ from each other in terms of 
mean IPA. With this increase in IPA, there was also an increase 
in bleeding with ticagrelor compared with clopidogrel. Most 
of the bleeding events were considered to be mild to moderate 
in severity. There was one major bleed in the ticagrelor group 
(400 mg once daily) that was gastrointestinal in nature. There 
was also an increased incidence of dyspnea in the ticagrelor 
group compared with the clopidogrel group which appeared 
to be dose-dependent, occurring with greatest severity in the 
patients receiving 400 mg once daily. The severity of dysp-
nea varied from mild to moderate, with a total of 29 reported 
instances of dyspnea, 21 of which were considered mild and 
eight were considered to be moderate.
Clopidogrel is the classic thienopyridine and the most 
popular nonaspirin antiplatelet agent used today. However, 
there are several limitations of clopidogrel therapy, mostly 
related to interpatient variability in pharmacologic effects. 
A substudy of the PLATelet inhibition and patient Outcomes 
(PLATO) trial (ie, PLATO PLATELET) showed ticagrelor 
to have greater and more consistent platelet inhibition than 
clopidogrel and did not increase the risk of bleeding.22 The two 
cohorts that were evaluated in this substudy were 69 patients 
who had received either clopidogrel (300–600 mg loading 
dose followed by 75 mg per day) or ticagrelor (180 mg load-
ing dose followed by 90 mg twice a day) for at least 28 days 
and 24 patients who had not received the study medication 
and have not received clopidogrel treatment within the 
  previous 14 days. The three methods that were used to study 
platelet aggregation were light transmittance aggregometry 
(LTA), the VerifyNow P2Y12 assay (Accumetrics, Inc, San 
Diego, CA), and vasodilator-stimulated phosphoprotein. The 
LTA method uses ADP to stimulate platelet aggregation in 
ex vivo blood samples. A higher response to ADP (measured 
in µM) indicates more platelet aggregation. The VerifyNow 
P2Y12 assay evaluates baseline platelet function through the 
thrombin receptor-activating peptide channel and the com-
bination of ADP and prostaglandin E1. The ADP is used to 
activate platelets through interaction with P2Y1 and P2Y12 
receptors, while prostaglandin E1 is used to suppress ADP 
platelet activation via the P2Y1 receptor. A percent change 
is calculated from the baseline platelet function and results 
reported using P2Y12 reaction units. The threshold of .235 
P2Y12 reaction units has been determined to be associated 
with an increased ischemic risk. Vasodilator-stimulated phos-
phoprotein measures the platelet reactivity index in which a 
threshold of .50% was determined to be associated with an 
increased ischemic risk. In all three studies of platelet aggre-
gation, ticagrelor showed more suppression of platelets than 
clopidogrel in both peak and trough plasma concentrations. 
Loading doses of ticagrelor showed more platelet inhibition 
at one hour compared with clopidogrel.
Ticagrelor is not a prodrug and does not have to be 
metabolically activated to have an antiplatelet effect, while 
clopidogrel is a prodrug which needs to be activated before 
eliciting a pharmacologic effect. The bioactivation of 
clopidogrel occurs in two sequential steps in the liver, with 
one pathway going through the CYP system, particularly 
CYP2C19. Once clopidogrel is activated by this enzyme, the 
active metabolite can inhibit platelets. This bioactivation of 
clopidogrel takes time and is evident even with loading doses 
of clopidogrel. A loading dose of clopidogrel significantly 
shortens the time to achieve maximal IPA; without a load-
ing dose, it takes approximately 5 days to reach maximal 
IPA with clopidogrel 75 mg once daily.23 With 300 mg and 
600 mg loading doses of clopidogrel, it takes about 4–8 hours 
to reach the final extent of platelet aggregation inhibition (ie, 
IPA observed at the end of the platelet aggregation response), 
which is about 30% and 45%–50%, respectively, for the 
300 mg and 600 mg doses of clopidogrel.15,24 This is in com-
parison with ticagrelor in which the final IPA of 80%–90% 
is reached approximately 2–4 hours after a 180 mg loading 
dose (Table 1).15,24
The ONSET/OFFSET study was a randomized, multi-
center, double-blind trial to evaluate the time to onset and 
offset of antiplatelet effects of ticagrelor 90 mg given twice Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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daily compared with placebo and clopidogrel 75 mg once 
daily.15 This study included patients with stable coronary 
artery disease who were receiving low-dose (75–100 mg 
per day) aspirin therapy. Patients were divided into one of 
three groups, ie, ticagrelor (n = 57), clopidogrel (n = 54), 
or placebo (n = 12). The ticagrelor and clopidogrel groups 
received loading doses (180 mg and 600 mg, respectively) 
before receiving the maintenance dosages. Fifty patients in 
each of the treatment arms were necessary for a 91% power 
to detect mean differences in IPA of 15% or more in the 
two treatment groups. Platelet function was determined by 
the use of three tests, ie, LTA, the VerifyNow P2Y12 assay, 
and vasodilator-stimulated phosphoprotein-P. The primary 
outcome for onset was IPA (20 µmol/L ADP) at 2 hours post 
initial dose, and offset was assessed by the slope of the IPA 
between 4 and 72 hours after the final study dose. The primary 
outcome was much greater in the ticagrelor group compared 
with the clopidogrel group (88% versus 38%, P , 0.0001). 
There was no difference in IPA in the ticagrelor group at 
2 hours and 8 hours post loading dose, while IPA was greater 
in the clopidogrel group at 8 hours compared with 2 hours 
post loading dose (P = 0.02). The maximum IPA was much 
higher in the ticagrelor group (93%) when compared with the 
clopidogrel group (58%) after the loading dose (P value not 
reported). The time to reach maximum IPA was faster in the 
ticagrelor group (2.0 hours) compared with the clopidogrel 
group (7.8 hours; P value not reported). Ticagrelor also had a 
faster offset of antiplatelet action compared with clopidogrel. 
The primary outcome for offset was higher in the ticagrelor 
group than in the clopidogrel group (P , 0.0001).
A subanalysis of the ONSET/OFFSET data focused on the 
offset of antiplatelet action of both ticagrelor and clopidogrel 
with a high antiplatelet drug response.25 Platelet activity was 
evaluated in this study in a similar fashion to the other studies 
discussed in this section. All three tests, LTA, VerifyNow, and 
vasodilator-stimulated phosphoprotein-P, showed significant 
differences in platelet function for ticagrelor compared with 
clopidogrel at 48 hours after the last dose was given. The IPA 
at 48 hours for clopidogrel was approximately 60% compared 
with less than 40% for ticagrelor (P , 0.01). There was good 
recovery of platelet function by 72 hours in patients treated 
with ticagrelor, with IPAs of about 20% in patients with 
high platelet reactivity and about 10% in patients without 
high platelet reactivity. This is in comparison with values of 
about 45% and 20%, respectively, for clopidogrel. The IPA 
for ticagrelor after 2 days (36%) was similar to the IPA for 
clopidogrel after 5 days (33%) from the last treatment dose. 
Since it is recommended that clopidogrel be withheld 5 days 
prior to surgery,26 these data can be useful for gauging how 
long a clinician should withhold ticagrelor before an invasive 
procedure. While the prescribing information for ticagrelor 
recommends discontinuation of ticagrelor 5 days prior to 
surgery,20 one can argue for a shorter window of about 3 days 
based on the ONSET/OFFSET data.
Clinical trials
The clinical trial program for ticagrelor is weighted heavily 
on two studies, ie, DISPERSE-227 and the PLATelet inhibi-
tion and patient Outcomes (PLATO) trial.28 Based on the 
original DISPERSE trial, which demonstrated good safety 
and tolerability and superior antiplatelet efficacy with 100 mg 
and 200 mg twice daily dosages of ticagrelor compared 
with clopidogrel,17 the multicenter DISPERSE-2 trial was 
performed to analyze the safety and efficacy of ticagrelor in 
984 patients with non-ST elevation ACS. These patients were 
randomized in a double-blind fashion to receive ticagrelor 
90 mg twice daily (n = 334), ticagrelor 180 mg twice daily 
(n = 323), or clopidogrel 75 mg once daily following a 
300 mg loading dose (n = 327) in addition to aspirin and 
other adjunctive therapies. It should be noted that the 90 mg 
and 180 mg doses of ticagrelor used in DISPERSE-2 were 
reformulations of the 100 mg and 200 mg doses used in 
  DISPERSE. The primary endpoint of major or minor bleeding 
at 4 weeks was seen with similar frequencies in each group 
(P = not statistically significant [NS]): 8.1% (clopidogrel), 
9.8% (ticagrelor 90 mg), and 8.0% (ticagrelor 180 mg). 
When major and minor bleeds were analyzed separately, 
the only statistically significant difference was that minor 
bleeds were seen more frequently with 180 mg twice daily 
of ticagrelor compared with clopidogrel at 4 weeks (1.3% 
Table 1 Comparison of P2Y12 receptor inhibitors15,20,24,26,58
Drug Bioactivation Receptor  
binding
Maximum  
IPA (%)*
Time to maximum  
IPA (hours)*
Half-life of active  
drug (hours)
Offset of antiplatelet   
action (days)†
Ticagrelor No Reversible 80–90 2–4 8–12 3
Prasugrel Yes, one step P-450 activation irreversible 75–80 2–4 7§ 5–7
Clopidogrel Yes, two step P-450 activation irreversible 30–50 4–8 0.5§ 5–7
Notes: *After a loading dose; †time to achieve platelet aggregation of #20%; §pharmacologic effects are much longer due to irreversible receptor binding.
Abbreviation: iPA, inhibition of platelet aggregation.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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versus 3.8%; P = 0.05) and at 12 weeks (1.3% versus 6.1%; 
P = 0.01). With regards to the secondary endpoint of major 
adverse cardiovascular events (myocardial infarction [MI], 
death, stroke, severe recurrent ischemia), a favorable trend 
was seen only with the ticagrelor 180 mg group compared 
with clopidogrel in terms of fewer MIs at 4 weeks (3.5% 
versus 1.0%; P = 0.047) and 12 weeks (5.6% versus 2.5%; 
P = 0.06). Nonhemorrhagic adverse events were comparable 
between the clopidogrel, 90 mg ticagrelor, and 180 mg 
ticagrelor groups except for dyspnea (6.4%, 10.5% [P = 0.07 
versus clopidogrel] and 15.8% [P , 0.0002 versus clopi-
dogrel], respectively), nausea (3.4%, 6.6% and 6.5% [both 
P = 0.07 versus clopidogrel]), diarrhea (3.4%, 3.0% [P = NS 
versus clopidogrel] and 7.4% (P = 0.02 versus clopidogrel), 
hypotension (0.6%, 4.2% [P = 0.004 versus clopidogrel] 
and 3.7% [P = 0.01 versus clopidogrel]), and asymptomatic 
ventricular pauses . 2.5 seconds (4.3%, 5.5% [P = NS versus 
clopidogrel] and 9.9% [P = 0.014 versus clopidogrel]). A sub-
group of patients (n = 330) received a 270 mg loading dose 
of ticagrelor prior to their maintenance dosage, but this was 
found to have no impact on the rate of the primary endpoint. 
In summary, DISPERSE-2 demonstrated 90 mg ticagrelor 
twice daily to possess similar safety and efficacy compared 
with clopidogrel, and ticagrelor 180 mg twice daily to have 
poorer safety compared with clopidogrel. Accordingly, the 
90 mg twice daily dose of ticagrelor was pursued further in 
clinical development with the PLATO trial.
The multicenter PLATO trial randomized 18,624 
patients with ACS (symptom onset within 24 hours) to 
receive   double-blind treatment with either ticagrelor 90 mg 
twice daily following a 180 mg loading dose (n = 9333) 
or clopidogrel 75 mg once daily following a 300–600 mg 
loading dose (n = 9291).28 All patients also received aspirin 
75–100 mg daily (325 mg daily was permitted for 6 months 
after stent placement). The final diagnosis was ST eleva-
tion MI in 38% of patients, non-ST elevation MI in 43%, 
and unstable angina in 17%; 64% underwent percutaneous 
intervention during the study period and 10% underwent 
coronary artery bypass grafting (CABG). The primary 
endpoint of vascular death, MI, or stroke at 12 months 
(median duration of treatment was 277 days) occurred in 
9.8% of patients receiving ticagrelor and 11.7% of patients 
receiving clopidogrel (hazard ratio [HR] 0.84; 95% confi-
dence interval [CI] 0.77–0.92; P , 0.001). As individual 
endpoints, ticagrelor resulted in significant reductions in 
vascular death (4.0% versus 5.1%; P = 0.001) and MI (5.8% 
versus 6.9%; P = 0.005), but not stroke (1.5 versus 1.3%; 
P = 0.22). Total mortality (4.5% versus 5.9%; P , 0.001) and 
stent   thrombosis (1.3% versus 1.9%; P = 0.009) were also 
lower with ticagrelor. Major bleeding rates were comparable 
between ticagrelor and clopidogrel (11.6% versus 11.2%; 
P = 0.43), although combined major and minor bleeding was 
greater with ticagrelor (16.1% versus 14.6%; P = 0.008), 
as was non-CABG-related major bleeding (4.5% versus 
3.8%; P = 0.03) and fatal intracranial bleeding (0.1 versus 
0.01%; P = 0.02), although fatal nonintracranial bleeding 
was higher with clopidogrel (0.3% versus 0.1%; P = 0.03). 
Despite the low event rates, intracranial bleeding is enough 
of a concern that prior intracranial hemorrhage is a contrain-
dication to ticagrelor therapy.20 As with the DISPERSE-2 
trial, dyspnea was the major nonhemorrhagic side effect of 
ticagrelor, occurring in 13.8% of patients (7.8% clopidogrel; 
P , 0.001) and leading to discontinuation of study treatment 
in 0.9% of patients (0.1% clopidogrel; P , 0.001). While 
ventricular pauses of at least 3 seconds were more common 
with ticagrelor during the first week of treatment (5.8% of 
patients versus 3.6% with clopidogrel; P = 0.01), these had 
subsided by 30 days of treatment (2.1% versus 1.7% clopi-
dogrel; P = 0.52) and were rarely   symptomatic. Increases 
in serum uric acid (15% versus 7%) and serum creatinine 
(11% versus 9%) at 12 months were also more common 
with ticagrelor compared with clopidogrel (P , 0.001 
for both).
Several subanalyses of the PLATO trial have been pub-
lished, which corroborate the overall result of the parent 
trial. Specifically, patients with ST elevation MI intended for 
reperfusion with primary percutaneous coronary intervention 
(n = 7544),29 patients intended for noninvasive management of 
ACS (n = 5216),30 patients intended for invasive management 
of ACS (n = 13,408),31 patients undergoing CABG (n = 1899),32 
patients with diabetes (n = 4662),33 and patients with chronic 
kidney disease (creatinine clearance , 60 mL/min; n = 3237)34 
all demonstrated efficacy and safety with ticagrelor similar to 
that seen in the original PLATO trial.
Sixty-six different predefined subgroups were analyzed in 
PLATO, 33 looking at the primary efficacy endpoint (eight 
of which were defined post hoc rather than predefined) and 
33 looking at major bleeding. With regards to efficacy, 30 of 
33 subgroups showed ticagrelor to be more efficacious than 
clopidogrel; the three subgroups that showed no efficacy 
benefit with ticagrelor compared with clopidogrel were: 
patients enrolled in North American sites (HR 1.25, 95% 
CI 0.93–1.67); males ,82 kg or females ,71 kg (HR 0.93, 
95% CI 0.82–1.05); and patients not taking a lipid-lowering 
drug (HR 1.02, 95% CI 0.83–1.24).28 For major bleeding, 
ticagrelor was similar to clopidogrel in all subgroups except Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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those patients with a body mass index of 30 kg/m2 or greater, 
who experienced more major bleeding with ticagrelor (HR 
1.21, 95% CI 1.02–1.45; P = 0.05). Of particular concern was 
the North American subgroup, which not only demonstrated 
a lack of benefit from ticagrelor compared with clopidogrel, 
but actually suggested that perhaps clopidogrel was a more 
efficacious drug in this population.28 This finding initially 
led the United States Food and Drug Administration not to 
approve ticagrelor in the United States in 2010 pending further 
investigation of this geographic phenomenon. After several 
months of deliberation and data analysis by two independent 
statistical groups, it was concluded that the trial conduct was 
appropriate and that this phenomenon might have been a play 
of chance.35 However, of 37 different factors studied in effect 
modifier analyses, aspirin dosage stood out as the most likely 
explanation for the regional differences in treatment effect. 
Specifically, 53.6% of patients in the United States took a 
median daily aspirin dosage of at least 300 mg compared with 
1.7% in the rest of the world. In the United States, patients tak-
ing at least 300 mg per day of aspirin, the HR for the primary 
efficacy endpoint was 1.62 (95% CI 0.99–2.64), suggesting 
benefit with clopidogrel over ticagrelor. When lower daily 
dosages of aspirin were analyzed (#100 mg), ticagrelor actu-
ally demonstrated a benefit in the United States population 
similar to that seen in the rest of the world (Figure 3).35 For 
this reason, the United States labeling for ticagrelor clearly 
states that maintenance dosages of aspirin should not exceed 
100 mg daily for patients taking ticagrelor.20
The clinical trial program with ticagrelor continues with 
the ongoing PEGASUS-TIMI 54 trial being conducted by the 
Thrombolysis in Myocardial Infarction (TIMI) investigators. 
PEGASUS (Prevention of Cardiovascular Events in Patients 
with Prior Heart Attack Using Ticagrelor Compared with 
Placebo on a Background of Aspirin) is expected to enroll 
21,000 post-MI patients with stable coronary artery disease 
from 30 countries, with 25% of subjects expected to be from 
the United States. The primary endpoint is cardiovascular 
death, nonfatal MI, or nonfatal stroke. The three treatments 
being studied are ticagrelor 90 mg twice daily, ticagrelor 
60 mg twice daily, and placebo. This study is scheduled to 
be completed in February 2014.36
Adverse effects
As mentioned above, the PLATO study demonstrated, not 
unexpectedly, that bleeding was the most common adverse 
effect seen with ticagrelor therapy, with major or minor 
bleeds occurring in 16.1% of patients (versus 14.6% with 
clopidogrel; P = 0.008).28 However, ticagrelor also has 
several off-target adverse effects (Table 2), arguably one of 
the more concerning being dyspnea. The DISPERSE-2 trial 
demonstrated a dose-response relationship with ticagrelor 
and dyspnea, with a 10.5% incidence of this adverse effect 
with ticagrelor 90 mg twice daily and a 15.8% incidence 
with 180 mg twice daily (versus 6.4% with clopidogrel).27 A 
subgroup analysis of the ONSET/OFFSET trial assessed car-
diopulmonary function in 123 patients receiving ticagrelor 
90 mg twice daily, clopidogrel 75 mg once daily, or   placebo.37 
The investigators were mainly interested in dyspnea, defined 
as shortness of breath either during exercise or at rest and 
was graded as mild, moderate, or severe.   Cardiopulmonary 
evaluations were evaluated at baseline and at the end of 6 
weeks of treatment or sooner if dyspnea or other adverse 
events were recorded. Dyspnea occurred in 38.6%, 9.3%, 
and 8.3% of patients in the ticagrelor group, clopidogrel 
group, and placebo group, respectively (  ticagrelor versus 
clopidogrel, P , 0.001; ticagrelor versus placebo, P , 0.05; 
clopidogrel versus placebo, not statistically significant). 
Most of the cases of dyspnea were considered mild in nature 
with only three cases in the ticagrelor group deemed to be of 
moderate severity. Three patients stopped taking the study 
treatment (all were taking ticagrelor) due to dyspnea; two 
were categorized as moderate dyspnea and one as mild. No 
cases of dyspnea were deemed to be severe. In the ticagre-
lor group, 17 of the 22 patients who experienced dyspnea 
had this occur within the first week of starting medication. 
While many cases of dyspnea with ticagrelor lasted less 
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Figure 3 Hazard ratios and 95% confidence intervals (in parentheses) for the PLATO 
study population with regards to the primary efficacy endpoint subdivided by daily 
aspirin dosage and geographic region.  Daily dosages of aspirin . 300 mg were 
associated with a blunting of the benefit of ticagrelor, whereas dosages , 100 mg 
were associated with benefit of ticagrelor compared to clopidogrel. This finding 
was seen regardless of geographic region, but was most pronounced in the United 
States population which tended to use higher daily dosages of aspirin compared to 
the rest of the world.35
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than 24 hours, several patients experienced dyspnea over 
the duration of the study. Most cases of dyspnea resolved 
following drug discontinuation. Electrocardiography, 
echocardiography, and pulmonary function tests were also 
performed at baseline and after 6 weeks of treatment, none 
of which were significantly affected by ticagrelor.
Dyspnea and pulmonary function were also extensively 
analyzed in the PLATO trial, which demonstrated dyspnea 
rates of 13.8% with ticagrelor (versus 7.8% with clopidogrel; 
P , 0.001) and resulted in discontinuation of study treatment 
in 0.9% of patients (versus 0.1% clopidogrel; P , 0.001).28 
Overall, 14.5% of patients randomized to ticagrelor reported 
dyspnea at any point during the study (both on and off study 
treatment) compared with 8.7% of patients taking clopidogrel 
(P , 0.001).38 Of these cases, only 0.4% (ticagrelor) and 0.3% 
(clopidogrel) were deemed by the study investigator to be 
of severe intensity. The median onset of dyspnea symptoms 
was 23 days from the onset of therapy with ticagrelor versus 
43 days with clopidogrel (P , 0.0001). The majority of cases 
of dyspnea resolved either spontaneously or upon discon-
tinuation of medication. The overall efficacy and safety of 
ticagrelor with respect to major adverse cardiovascular events 
and bleeding did not appear to be affected by the presence of 
dyspnea.38 Pulmonary function studies were also performed 
in 199 patients in PLATO (101 patients receiving ticagrelor, 
98 patients receiving clopidogrel), with no significant 
changes in pulmonary function demonstrated with ticagrelor 
Table 2 Nonhemorrhagic side effects observed with ticagrelor 
in PLATO20,28
Ticagrelor  
(n = 9235)
Clopidogrel   
(n = 9186)
Dyspnea 13.8% 7.8%
Headache 6.5% 5.8%
Cough 4.9% 4.6%
Dizziness 4.5% 3.9%
Nausea 4.3% 3.8%
Atrial fibrillation 4.2% 4.6%
Hypertension 3.8% 4.0%
Non-cardiac chest pain 3.7% 3.3%
Diarrhea 3.7% 3.3%
Back pain 3.6% 3.3%
Hypotension 3.2% 3.3%
Fatigue 3.2% 3.2%
Chest pain 3.1% 3.5%
Gynecomastia 0.23% 0.05%
increase in serum  
creatinine . 50%
7.4% 5.9%
increase in serum uric acid  
from baseline
0.6 mg/dL 0.2 mg/dL
Note: Numbers are represented as percentage of patients unless stated otherwise. 
Abbreviation: PLATO, PLATelet inhibition and patient Outcomes.
administration in this subgroup.39 While the mechanism for 
ticagrelor-induced dyspnea had not been clearly elucidated, 
a popular hypothesis is that ticagrelor inhibits adenosine 
reuptake and thereby increases extracellular adenosine con-
centrations, and exogenous adenosine administration is known 
to cause dyspnea, perhaps through activation of A1 receptors 
and resulting stimulation of pulmonary vagal C fibers.38–40
Another concerning adverse effect with ticagrelor in 
clinical trials was a dose-related increase in the incidence of 
ventricular pauses. This was initially seen in the DISPERSE-2 
trial and was one factor in the abandonment of the 180 mg 
dosage of ticagrelor in late-phase clinical development.27 
A subgroup of 2908 patients in the PLATO trial underwent 
continuous ECG monitoring to document the frequency of 
ventricular pauses and clinical bradycardic events in patients 
taking ticagrelor (n = 1472) or clopidogrel (n = 1436).41 
Ventricular pauses lasting at least 3 seconds occurred more 
frequently with ticagrelor (5.8%) compared with clopidogrel 
(3.6%; P = 0.006) during the first week of therapy, but this 
difference was not significant after 30 days of treatment (2.1% 
versus 1.7% for ticagrelor and clopidogrel, respectively, 
P = 0.52). These pauses were largely asymptomatic, transient, 
nocturnal, and emanated from the sinus node. The incidence 
of clinically reported bradycardic adverse events did not differ 
between ticagrelor and clopidogrel through 12 months of fol-
low-up. As with ticagrelor-induced dyspnea, the mechanism(s) 
responsible for ventricular pauses with ticagrelor remain to be 
elucidated but may involve inhibition of adenosine reuptake by 
erythrocytes with resulting increases in adenosine concentra-
tions at the sinoatrial and atrioventicular nodes.41
In the PLATO trial, elevations in serum creatinine and uric 
acid were seen more frequently in patients taking ticagrelor 
compared with clopidogrel (Table 2).28 Concentrations of 
these compounds returned to baseline following drug discon-
tinuation. The mechanism(s) for this is unknown, but may 
be related to impaired purine catabolism due to increased 
adenosine concentrations.42 These side effects have not been 
attributed to either prasugrel or clopidogrel.
Drug interactions
As mentioned earlier, ticagrelor has the advantage over 
the thienopyridines of not requiring metabolic activation 
for activity. This would theoretically reduce the potential 
for drug-drug interactions with ticagrelor. Both CYP3A4 
and, to a lesser extent, CYP3A5 have been identified as 
the isozymes responsible for the formation of the active 
and inactive metabolites of ticagrelor.19 As such, strong 
inhibitors (ie, ketoconazole, itraconazole, clarithromycin, Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, 
atazanavir, telithromycin) or inducers (ie, rifampin, 
dexamethasone, phenytoin, carbamazepine, phenobarbital) 
of these enzymes may interfere with the activity of ticagre-
lor, and concomitant administration should be avoided.20 
Ticagrelor is also an inhibitor of CYP3A4 and CYP3A5 
and may increase serum concentrations of simvastatin and 
lovastatin which rely on CYP3A4 for metabolism. The daily 
dosages of simvastatin and lovastatin should not exceed 
40 mg when given in combination with ticagrelor.20 Ticagre-
lor is an inhibitor of the P-glycoprotein transporter and 
may therefore increase serum digoxin concentrations; these 
should be monitored with initiation or change in ticagrelor 
therapy.20 As mentioned above, aspirin dosage should not 
exceed 100 mg per day when given with ticagrelor due to a 
potential loss in ticagrelor efficacy. Ticagrelor can be safely 
administered with unfractionated or low-molecular-weight 
heparin, glycoprotein IIb/IIIa inhibitors, beta-blockers, 
angiotensin-converting enzyme inhibitors, angiotensin 
receptor antagonists, and proton pump inhibitors.20 Proton 
pump inhibitors have mechanistically been shown to inhibit 
CYP2C19, which may interfere with the activation of clopi-
dogrel. However, it is debatable as to whether or not giving 
clopidogrel in combination with a proton pump inhibitor 
is detrimental in terms of clinical outcomes.43,44 Because 
CYP2C19 is not a major metabolic pathway for ticagrelor 
metabolism, a potential pharmacokinetic interaction with 
proton pump inhibitors is not concerning.
Other practical considerations  
with ticagrelor therapy
The major efficacy and safety issues involving ticagrelor 
therapy have been discussed up to this point, but much more 
needs to be considered when deciding on how to integrate 
ticagrelor into clinical practice. Some of these issues are 
discussed below and summarized in Table 3.
Aspirin dosage
The prescribing information for ticagrelor contains a boxed 
warning regarding a potential loss of efficacy with ticagrelor 
when given concomitantly with daily aspirin dosages exceed-
ing 100 mg per day.20 The genesis of this warning is discussed 
earlier in this article, and clinicians and patients need to be 
aware of this and prescribe and consume aspirin in accor-
dance with this warning. While a biological explanation has 
not been clearly defined to explain why higher dosages of 
aspirin may blunt the effectiveness of ticagrelor, it has been 
hypothesized that some of the benefits of ticagrelor may be 
dependent on prostacyclin, the production of which may be 
blocked by daily doses of aspirin exceeding 80 mg.45 The 
reliance on prostacyclin for an antiplatelet effect may relate 
directly to the degree of P2Y12 inhibition, which would explain 
why the more potent ticagrelor would be more susceptible 
to an aspirin interaction than clopidogrel.45 In the absence 
of a clear explanation for an aspirin-ticagrelor interaction, 
some experts are reluctant to accept that such an interaction 
even exists.46 Even though the European countries in PLATO 
all used the same low daily dosage of aspirin, there were 
differences in outcomes among those countries, with some 
results favoring clopidogrel, some favoring ticagrelor, and 
some neutral, arguing that aspirin dosage did not impact the 
study results.46
Others have looked at the issue of an interaction between 
aspirin and ticagrelor from a different perspective, namely 
questioning whether or not aspirin is even needed when 
ticagrelor is being administered. This is a difficult question 
Table 3 Practical considerations when comparing clopidogrel, prasugrel, and ticagrelor
Clopidogrel Prasugrel Ticagrelor
indication(s) ACS; recent Mi, stroke, or  
established peripheral  
arterial disease
ACS with PCi ACS
Dosing frequency Once daily Once daily Twice daily
Concomitant aspirin dosage 75–325 mg/day 75–325 mg/day #100 mg/day
Pharmacogenomic variability in antiplatelet effect? Yes No No
Contraindications other than active bleeding  
or drug hypersensitivity
None Prior transient ischemic  
attack or stroke
Prior intracranial hemorrhage, 
severe hepatic impairment
interaction with proton pump inhibitors? Possible No No
AwP cost/30 days* $222.55 $222.16 $265.13
UNMH cost/30 days* $174.76 $174.45 N/A
Note: *Prices are expressed as United States dollars. 
Abbreviations: ACS, acute coronary syndrome; AwP, average wholesale price; Mi, myocardial infarction; N/A, not available; PCi, percutaneous coronary intervention; 
UNMH, University of New Mexico Hospital.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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to answer because aspirin is the standard of care for treat-
ment and prevention of atherothrombotic disease and the 
thienopyridines and ticagrelor are added to, rather than given 
in place of, aspirin in clinical trials for ethical reasons. From 
a pharmacologic perspective, potent P2Y12 receptor block-
ade leads to a reduction in the ability of platelets to produce 
thromboxane A2, the primary target for the antiplatelet effect 
of aspirin.45,47 Accordingly, it has been questioned whether or 
not aspirin is having much, if any, antiplatelet effect in this 
setting because the potent P2Y12 antagonists are essentially 
serving an aspirin-like function in suppressing thromboxane 
A2 production. In this scenario, aspirin may paradoxically 
be detrimental, because it may then function primarily 
to suppress production of beneficial prostanoids such as 
  prostaglandin I2.45 While prostanoid inhibition is also seen 
with aspirin monotherapy, the beneficial antiplatelet effect 
may outweigh any detrimental effects on prostanoid produc-
tion, resulting in a net clinical benefit.45 The determination of 
how much incremental benefit aspirin adds to thienopyridine 
or ticagrelor therapy needs to be investigated in clinical tri-
als before any conclusions can be made in this regard. For 
now, published clinical studies support the combination of a 
P2Y12 receptor antagonist with aspirin and clinical practice 
should reflect this.
Efficacy in clopidogrel nonresponders
It has been fairly well established that there is interpatient 
variability in the antiplatelet effects of clopidogrel, which is 
largely believed to be due to genetic polymorphisms of the 
CYP2C19 enzyme responsible for converting clopidogrel to 
its active form.48,49 It has been documented that the frequen-
cies of poor metabolizers of CYP2C19 are 2% in White, 
4% in Black, and 14% in Chinese racial groups.26 The two 
polymorphisms that account for nonfunctional CYP2C19 
enzymes are CYP2C19*2 and *3 which are seen in 85% of 
White and 99% of Asian poor metabolizers.26 Major adverse 
cardiovascular events have been shown to occur more often in 
patients with reduced CYP2C19 function taking clopidogrel 
compared with those having good CYP2C19 function.50 
Genetic testing for CYP2C19 polymorphisms is now com-
mercially available and is beginning to gain traction as a 
means of screening patients to predict the antiplatelet efficacy 
of clopidogrel. Patients who have a diminished antiplatelet 
effect in response to clopidogrel are deemed “nonresponders” 
or “poor responders”, and a proven alternative antiplatelet 
therapy for these patients would be very desirable.
The Response to Ticagrelor in Clopidogrel Nonre-
sponders and Responders and Effect of Switching Therapies 
(RESPOND) study was designed to investigate the anti-
platelet effect of ticagrelor in clopidogrel nonresponders.51 
Clopidogrel response was judged in 98 patients with stable 
coronary artery disease based on ADP-induced platelet 
aggregation following administration of a 300 mg loading 
dose of clopidogrel. Inhibition of platelet aggregation using 
LTA of .10% defined clopidogrel response and #10% clopi-
dogrel nonresponse. After being categorized as a clopidogrel 
responder (n = 57) or nonresponder (n = 41), patients were 
randomly assigned to receive one of two double-blind treat-
ments, ie, a 600 mg clopidogrel load followed by 75 mg once 
daily for 14 ± 2 days or a 180 mg ticagrelor load followed 
by 90 mg twice daily for 14 ± 2 days. After this initial study 
phase, all of the nonresponders switched study treatments, 
while only half of the responders switched treatments (the 
other half remained on the same treatment), which were 
also given for 14 ± 2 days. All patients also received aspirin 
75–100 mg once daily. Of the patients initially identified as 
nonresponders to clopidogrel, 100% responded to ticagrelor 
after 2 weeks of treatment, defined as a .10% decrease in 
platelet aggregation from baseline. This is in comparison with 
a 75% response rate for clopidogrel (P = 0.005). Decreases 
in platelet aggregation of .30% and .50% were seen in 
75% and 13% of ticagrelor patients, respectively, compared 
with 13% (P , 0.001) and 0% (P = 0.046) of patients 
receiving clopidogrel. Mean platelet aggregation increased 
from 36% to 56% (P , 0.0001) in the patients who crossed 
over to receive clopidogrel (initially on ticagrelor) in the 
second phase of the study, whereas those patients who were 
initially on clopidogrel and crossed over to receive ticagrelor 
demonstrated a decrease in mean platelet aggregation from 
59% to 35% (P , 0.0001). In patients initially identified as 
clopidogrel responders, ticagrelor consistently demonstrated 
greater inhibition of platelet aggregation both before and after 
treatment crossover. These results not only demonstrated that 
ticagrelor was superior to clopidogrel in terms of inhibiting 
platelet aggregation both in clopidogrel responders and 
nonresponders, but also that ticagrelor is effective in patients 
who do not demonstrate an antiplatelet effect in response to 
clopidogrel, producing inhibition of platelet aggregation in 
these patients that is comparable with that seen in clopidogrel 
responders.
Genetic substudies were performed in the RESPOND, 
ONSET/OFFSET, and PLATO trials in an attempt to 
determine the effect of CYP2C19 metabolizer status on the 
efficacy of ticagrelor and clopidogrel.52,53 The combined 
data from RESPOND and ONSET/OFFSET demonstrated 
the antiplatelet effects of clopidogrel to be dependent on the Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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CYP2C19 genotype, with loss-of-function carriers (ie, poor 
metabolizers) and intermediate metabolizers having a higher 
degree of platelet function. No such relationship was seen 
with ticagrelor.52 In the PLATO genetic substudy, patients 
with a loss-of-function CYP2C19 allele receiving clopidogrel 
had a higher incidence of the primary endpoint of major 
adverse cardiovascular events compared with patients receiv-
ing clopidogrel who did not have any loss-of-function alleles. 
The event rate with ticagrelor was similar regardless of 
CYP2C19 polymorphisms.53
Together, these studies demonstrate ticagrelor to have 
comparable efficacy regardless of CYP2C19 metabolizer 
status, unlike clopidogrel, and to be a viable alternative to 
clopidogrel in those patients deemed to be nonresponders 
to clopidogrel.
Economics
As with many new medications, drug cost promises to be a 
critical factor in determining the current place in therapy for 
ticagrelor, particularly with the pending generic availability 
of clopidogrel (expected May 2012 in the United States). 
While the acquisition cost of ticagrelor will in all probability 
be higher than generic clopidogrel, economic factors other 
than drug cost itself need to be considered when deciding 
on the status of clopidogrel by institutional and health plan 
formularies. Cost effectiveness data would represent one 
of these factors, and data with ticagrelor have just recently 
started to emerge in this regard.
An unpublished health economics substudy (available 
in abstract form only) from PLATO compared quality-
adjusted like years (QALY) for ticagrelor and clopidogrel.54 
Based on PLATO event rates and drug costs of €0.17 ($0.23 
United States dollars [USD]) per day for generic clopidogrel 
and €2.25 ($3.00) to €3.50 ($4.65) per day for ticagrelor, 
health care costs (based on Swedish base-case analysis) and 
QALYs were estimated. The results showed that patients 
receiving ticagrelor would be expected to gain an additional 
0.13 QALYs at a cost of €2350 ($3110) to €5700 ($7550) 
per QALY compared with clopidogrel. This would indicate 
ticagrelor to be cost effective compared with clopidogrel 
since a threshold of €38,000 ($50,000) per QALY is typically 
used to determine cost effectiveness in the United States. 
Another cost effectiveness analysis focused on comparing 
ticagrelor with genotype-driven therapy with clopidogrel in 
a cohort of Medicare patients with ACS.55 That study dem-
onstrated an incremental cost effectiveness ratio of $10,059 
USD per QALY with ticagrelor therapy compared with 
genotype-driven clopidogrel therapy over a 5-year period. 
Even in a simulation in which clopidogrel was $4 USD per 
month, the cost effectiveness ratio would be $11,927 USD 
per QALY with ticagrelor. It is estimated that ticagrelor 
would remain cost effective compared with genotype-driven 
clopidogrel therapy as long as the monthly cost of ticagrelor 
did not exceed $693 USD per month. The average wholesale 
price at the time of writing for one month of ticagrelor therapy 
is $265 USD (Table 3).
Medication adherence
As mentioned above, ticagrelor not only has a rapid onset 
in terms of antiplatelet activity, but it also has a faster 
offset than the thienopyridines. This may be beneficial, as 
mentioned earlier, in potentially decreasing the waiting time 
to surgery, especially if a patient needs CABG. However, 
there is also some concern that the relatively fast offset of 
antiplatelet effect may make medication adherence that much 
more important with ticagrelor. It has been shown that the 
antiplatelet effects of ticagrelor drop more precipitously than 
clopidogrel between 8 and 24 hours post-dose, although the 
IPA with ticagrelor seems to be maintained at a level com-
parable to or greater than clopidogrel over this time period. 
However, by 48 hours post dose, the IPA with ticagrelor is 
less than that seen with clopidogrel; by 72 hours post dose, the 
IPA with ticagrelor is about 20%, which is comparable with 
that seen 5–7 days after discontinuation of clopidogrel.15,25 
While there are no studies that have looked at clinical out-
comes related to the offset of action of ticagrelor, measures 
should be taken to ensure that patients will be adherent with 
ticagrelor, and/or support needs to be given to those patients 
who have a history of poor adherence to other drugs. This is 
of added concern because ticagrelor needs to be taken twice 
daily, and medication adherence is inversely related to the 
number of daily doses.56 Patients need to be aware of the 
importance of not missing a dose and have a plan of action 
in case circumstances arise which would jeopardize adher-
ence; for example, carrying extra tablets with them on trips 
in the event of an airplane flight cancellation which would 
extend their time away from home.
Clinical comparison versus 
prasugrel
There are no head-to-head comparisons with ticagrelor 
and prasugrel in terms of clinical outcomes. Prasugrel is a 
thienopyridine prodrug so, like clopidogrel requires bioac-
tivation in order to produce a pharmacologic effect. Unlike 
clopidogrel, the bioactivation of prasugrel requires only 
one step instead of two. This drug is initially hydrolyzed in Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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the intestines by esterases and converted to the active form 
primarily by CYP3A4 and CYP2B6.57 The time to maximal 
IPA is slightly faster than clopidogrel with a loading dose, 
and prasugrel does have a higher maximal IPA compared 
with clopidogrel.58 The typical loading dose of prasugrel is 
60 mg, which will lead to a maximal IPA of about 80% in 
approximately 2–4 hours (Table 1).57 A head-to-head com-
parison of ticagrelor and prasugrel demonstrated more potent 
inhibition of platelet aggregation with ticagrelor.47
Because prasugrel has the same mechanism of action 
as clopidogrel, it irreversibly inhibits platelets and needs 
approximately 7 days for the antiplatelet effects to wear 
off completely, given that new platelets will need to be 
  synthesized. While more efficacious than clopidogrel, clinical 
trials have shown an increase in life-threatening, major, and 
fatal bleeds with prasugrel compared with clopidogrel.8 The 
bleeding risk was higher in specific subgroups of patients, 
including those who were 75 years of age or older, those 
who weighed less than 60 kilograms, and those who had a 
history of stroke or transient ischemic attacks.8 Prasugrel also 
showed no efficacy advantage over clopidogrel in terms of 
reducing major adverse cardiovascular events in these sub-
groups of patients. Restrictions have therefore been placed 
on prasugrel, and this drug carries a boxed warning because 
of the bleeding risks. Prasugrel should not be used in patients 
with a history of stroke or TIA. Extreme caution should be 
used in patients who are at least 75 years of age or weigh 
less than 60 kilograms.57 A meta-analysis indirectly compar-
ing bleeding with ticagrelor and prasugrel was in favor of 
less bleeding with ticagrelor.59 While bleeding rates were 
higher with prasugrel than clopidogrel in TRITON-TIMI 
388 and comparable between ticagrelor and clopidogrel in 
PLATO,28 when one compares bleeding rates according to the 
standardized TIMI criteria, one finds that, on a percentage-
by-percentage basis, a higher percentage of patients taking 
ticagrelor in PLATO experienced non-CABG-related major 
bleeding as well as major or minor bleeding, both defined 
by TIMI criteria, compared with patients taking prasugrel in 
TRITON-TIMI 38 (Table 4). However, a greater percentage 
of patients taking prasugrel in TRITON-TIMI 38 reported 
major CABG-related bleeding compared with patients tak-
ing ticagrelor in PLATO. Bleeding rates with clopidogrel 
were higher in the PLATO trial compared with TRITON-
TIMI 38, even though both studies used similar clopidogrel 
doses, with the exception that 20% of patients in PLATO 
received a 600 mg loading dose of clopidogrel instead of the 
standard 300 mg loading dose (Table 4). Another difference 
is that the PLATO trial enrolled patients even if they had 
received clopidogrel before randomization, while patients 
in the   TRITON-TIMI 38 study had to have discontinued 
clopidogrel for at least 5 days before randomization. It is 
unknown whether or not these differences in clopidogrel 
treatment contributed in any way to the higher bleeding rates 
with clopidogrel in PLATO versus TRITON-TIMI 38, thereby 
narrowing the window of difference between ticagrelor and 
clopidogrel in terms of bleeding rates, but these cannot be 
dismissed as contributing factors. It is also noteworthy that 
the major safety endpoint in PLATO was study-defined major 
bleeding, and it was non-CABG-related major TIMI bleeding 
in TRITON TIMI 38. This is not to say that prasugrel and 
ticagrelor are comparable in any way with regards to bleed-
ing, because this was an indirect comparison and absolute 
numbers of bleeds were substantially lower in the TRITON-
TIMI 38 trial by virtue of an overall smaller sample size in 
relation to the PLATO study. However, it does argue for a 
standardized definition of bleeding in clinical trials in order 
to facilitate indirect comparisons such as these for which no 
direct head-to-head data exist.60
Both prasugrel and ticagrelor have shown superior-
ity in efficacy over clopidogrel in patients with ACS.8,28 
However, since these two new antiplatelet agents do not 
have any direct head-to-head comparison trials, the choice 
of which one to use in lieu of clopidogrel is not clear. An 
indirect comparative meta-analysis has been published to 
attempt to clarify this issue.59 This meta-analysis compared 
these two new antiplatelet agents indirectly through their 
Table 4 Bleeding rates in the PLATO and TRiTON-TiMi 38 trials based on TiMi criteria8,28
PLATO TRITON-TIMI 38
Ticagrelor Clopidogrel P value Prasugrel Clopidogrel P value
CABG-related major bleeding* 5.3 5.8 0.32 13.4 3.2 ,0.001
Non-CABG-related major bleeding* 2.8 2.2 0.03 2.4† 1.8† 0.03
Major or minor bleeding* 11.4 10.9 0.33 5.0 3.8 0.002
Major bleeding, study criteria 11.6† 11.2† 0.43 NA NA NA
Notes: *According to TiMi criteria; †primary safety endpoint; numbers are expressed as percentage of patients. 
Abbreviations: NA, not applicable; PLATO, PLATelet inhibition and patient Outcomes; TiMi, Thrombolysis in Myocardial infarction.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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landmark trials, ie, PLATO for ticagrelor and TRITON-
TIMI 38 for prasugrel, and demonstrated no difference 
between these two drugs in terms of overall risk of death, 
nonfatal myocardial infarction, nonfatal stroke, or in their 
other composite endpoints. The only difference between 
the two drugs in terms of efficacy was that prasugrel 
was shown to have a significantly lower risk of definite 
or probable stent thrombosis (odds ratio = 0.64; 95% CI 
0.43–0.93; P = 0.020). The cost of this benefit was an 
increased risk of any major TIMI bleeding, major bleed-
ing associated with cardiac surgery, and major or minor 
TIMI bleeding with prasugrel.59 There have been conflict-
ing views in terms of the differences between ticagrelor 
and prasugrel when the clinical efficacy of these drugs is 
indirectly compared.42 Looking more closely at these two 
trials in terms of mortality, ticagrelor reduced mortality 
in PLATO (HR = 0.78; 95% CI 0.69–0.89; P , 0.001) 
whereas prasugrel did not in TRITON-TIMI 38 (HR 0.95; 
95% CI 0.78–1.16; P = 0.64). The PLATO trial allowed 
patients into the trial if they had received clopidogrel 
before randomization while patients in the TRITON-TIMI 
38 study had to be off clopidogrel for at least 5 days before 
randomization. This helps illustrate that the PLATO trial 
gives a more realistic view of what to expect when treating 
with these antiplatelet agents.
In terms of off-target adverse effects, ticagrelor may 
cause dyspnea and cardiac conduction abnormalities as men-
tioned above, which is not much of a concern with prasugrel 
therapy. Based on the premise that these side effects are due 
to ticagrelor-induced elevations in adenosine concentrations, 
one would not expect these side effects to occur with prasug-
rel.38,41 Additionally, ticagrelor may elevate serum creatinine 
and uric acid concentrations, which is not something that 
has been attributed to   prasugrel.   However, there is concern 
regarding cancer risk with   prasugrel. Specifically, a 27% 
increased risk in colorectal, lung, and breast malignan-
cies was seen in the TRITON-TIMI 38 trial with prasugrel 
compared with clopidogrel, primarily in women.42,61 How-
ever, this may very well be a chance finding, given that the 
absolute numbers of cases was low. In the PLATO study, the 
incidence of either any neoplasm or a malignant neoplasm 
arising during treatment was comparable between ticagrelor 
and clopidogrel, while the incidence of a benign neoplasm 
occurring was actually less with ticagrelor (0.2%) compared 
with clopidogrel (0.4%; P = 0.02).28
The potential efficacy of ticagrelor in clopidogrel 
nonresponders was discussed earlier, indicating that 
ticagrelor seems to be effective in these patients.52,53 Prasugrel 
has also been studied in patients with functional variants in 
clopidogrel-metabolizing enzymes and has shown potential 
in these patients as well.62,63 Because no head-to-head trials 
exist comparing ticagrelor with prasugrel in clopidogrel 
nonresponders, no conclusions can be made at this time 
regarding which agent to choose in this setting. Nonetheless, 
both prasugrel and ticagrelor have promise as alternative 
antiplatelet drugs for patients not responding adequately to 
clopidogrel.
Summary
Ticagrelor is the first reversible P2Y12 receptor antagonist 
to be available for clinical use. Compared with clopidogrel, 
ticagrelor elicits a faster and stronger antiplatelet effect and 
also displays greater clinical efficacy with a comparable rate 
of bleeding. Ticagrelor is indicated to be used with aspirin 
therapy, but only at aspirin dosages not exceeding 100 mg 
daily, because the clinical data suggest that ticagrelor may 
lose efficacy when combined with higher dosages of aspirin, 
although this is a topic of debate. The relatively fast offset 
of effect of ticagrelor is desirable in the sense that invasive 
procedures will not need to be delayed as long for fear of 
bleeding. However, the quicker offset of effect makes medi-
cation adherence that much more important, because miss-
ing consecutive doses may increase the risk for thrombotic 
events. This is even more concerning given that ticagrelor is 
administered twice daily, making adherence more challenging 
compared with medications that are administered once daily 
(eg, clopidogrel, prasugrel). Bleeding is the most common 
side effect with ticagrelor, although dyspnea, ventricular 
pauses, and elevations in serum creatinine and uric acid are 
also associated with ticagrelor therapy. Ticagrelor has been 
shown to inhibit platelet aggregation effectively in patients 
nonresponsive to clopidogrel, and there are currently no 
known pharmacogenetic issues with ticagrelor. Ticagrelor 
is currently competitively priced against clopidogrel and 
prasugrel, although with clopidogrel becoming available as 
a generic very soon, drug costs will likely be a consideration 
when delineating the role of ticagrelor in the treatment of 
coronary artery disease. Direct comparisons with prasugrel 
are unfortunately lacking, and the relative merits of ticagre-
lor and prasugrel will have to be made based on indirect 
comparisons. Ticagrelor is a very promising new antiplatelet 
drug with impressive efficacy and reasonable safety. While 
ticagrelor has currently established itself for the treatment 
of acute coronary syndromes, ongoing and future trials in 
broader clinical scenarios will hopefully establish more 
clearly its ultimate place in therapy.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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